IP Library › Granted Patent US 12,209,132
Granted Patent B2
US 12,209,132 · App. 18/464,998 · Granted Jan 28, 2025

Compositions and methods related to IL27 receptor binding

Inventors: Robert Kastelein (Menlo Park, CA); Patrick Lupardus (Menlo Park, CA); Deepti Rokkam (Menlo Park, CA)
Assignee: Synthekine, Inc.
C07K16/2866A61P37/02C07K14/7155C07K16/2803C07K16/46C07K16/468C07K19/00C12N15/63C12N15/86A61K2039/505C07K2317/22C07K2317/24C07K2317/31C07K2317/33C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/565C07K2317/567C07K2317/569C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,132
App. No.
18/464,998
Granted
Jan 28, 2025
Kind
B2
Abstract

Provided herein are IL27R binding proteins that bind to IL27Rα and gp130 and comprise an anti-IL27Rα V H H antibody and an anti-gp130 V H H antibody.

Claims (36)

1. An isolated nucleic acid encoding an IL27 receptor (IL27R) binding protein that specifically binds to IL27Rα subunit (IL27Rα) and glycoprotein 130 subunit (gp130),

wherein the binding protein comprises an anti-IL27Rα V H H antibody and an anti-gp130 V H H antibody, and

wherein the anti-gp130 V H H antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of:

SEQ ID NO: 193, SEQ ID NO: 199, SEQ ID NO: 205, respectively;

SEQ ID NO: 194, SEQ ID NO: 200, SEQ ID NO: 206, respectively;

SEQ ID NO: 195, SEQ ID NO: 201, SEQ ID NO: 207, respectively;

SEQ ID NO: 196, SEQ ID NO: 202, SEQ ID NO: 208, respectively;

SEQ ID NO: 197, SEQ ID NO: 203, SEQ ID NO: 209, respectively; and

SEQ ID NO: 198, SEQ ID NO: 204, SEQ ID NO: 210, respectively; and

the anti-IL27Rα V H H antibody comprises a set of a CDR1, a CDR2, and a CDR3, wherein the set is selected from the group consisting of

SEQ ID NO: 211, SEQ ID NO: 218, SEQ ID NO: 225, respectively;

SEQ ID NO: 212, SEQ ID NO: 219, SEQ ID NO: 226, respectively;

SEQ ID NO: 213, SEQ ID NO: 220, SEQ ID NO: 227, respectively;

SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively;

SEQ ID NO: 215, SEQ ID NO: 222, SEQ ID NO: 229, respectively;

SEQ ID NO: 216, SEQ ID NO: 223, SEQ ID NO: 230, respectively; and

SEQ ID NO: 217, SEQ ID NO: 224, SEQ ID NO: 231, respectively.

2. An expression vector comprising the nucleic acid of claim 1 .

3. An isolated cell comprising the vector of claim 2 .

4. The isolated nucleic acid of claim 1 , wherein the anti-gp130 V H H antibody comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 196, SEQ ID NO: 202, and SEQ ID NO: 208, respectively.

5. The isolated nucleic acid of claim 4 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively.

6. The isolated nucleic acid of claim 4 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 216, SEQ ID NO: 223 and SEQ ID NO: 230, respectively.

7. The isolated nucleic acid of claim 1 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 64.

8. The isolated nucleic acid of claim 1 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 76.

9. The expression vector of claim 2 , wherein the anti-gp130 V H H antibody comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 196, SEQ ID NO: 202, and SEQ ID NO: 208, respectively.

10. The expression vector of claim 9 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively.

11. The expression vector of claim 9 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 216, SEQ ID NO: 223 and SEQ ID NO: 230, respectively.

12. The expression vector of claim 2 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 64.

13. The expression vector of claim 2 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 76.

14. The isolated cell of claim 3 , wherein the anti-gp130 V H H antibody comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 196, SEQ ID NO: 202, and SEQ ID NO: 208, respectively.

15. The isolated cell of claim 14 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 214, SEQ ID NO: 221, SEQ ID NO: 228, respectively.

16. The isolated cell of claim 3 , wherein the anti-IL27Rα V H H antibody CDR1 comprises the set of CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NO: 216, SEQ ID NO: 223 and SEQ ID NO: 230, respectively.

17. The isolated cell of claim 3 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 64.

18. The isolated cell of claim 3 , wherein the IL27 receptor (IL27R) binding protein comprises an amino acid sequence of SEQ ID NO: 76.

19. A method of making the IL27 receptor (IL27R) binding protein that specifically binds to IL27Rα subunit (IL27Rα) and glycoprotein 130 subunit (gp130) from the cell of claim 3 , the method comprising,

culturing the cell to express the IL27 receptor (IL27R) binding protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2024
From: KASTELEIN, ROBERT; LUPARDUS, PATRICK; ROKKAM, DEEPTI
To: SYNTHEKINE, INC.
Reel/Frame 068594/0083 →
Continuity (6)
Continuation 18164386 · Feb 3, 2023
Continuation PCTUS2021044577 · Aug 4, 2021
Provisional Application 63061562 · Aug 5, 2020
Provisional Application 63078745 · Sep 15, 2020
Provisional Application 63135884 · Jan 11, 2021
Related Publication 20240209101A1 · Jun 27, 2024
References Cited (96)
US 8258268B2 · Wu et al. · 2012 [cited by applicant]
US 8921528B2 · Holt et al. · 2014 [cited by applicant]
US 8975382B2 · Revets et al. · 2015 [cited by applicant]
US 9334331B2 · Igawa · 2016 [cited by applicant]
US 10421807B2 · Gonzales · 2019 [cited by applicant]
US 10927186B2 · Roobrouck et al. · 2021 [cited by applicant]
US 20060024295A1 · Brunetta · 2006 [cited by applicant]
US 20100297127A1 · Ghilardi et al. · 2010 [cited by applicant]
US 20110028695A1 · Revets et al. · 2011 [cited by applicant]
US 20110053865A1 · Saunders et al. · 2011 [cited by applicant]
US 20110142831A1 · Cua et al. · 2011 [cited by applicant]
US 20120201746A1 · Liu et al. · 2012 [cited by applicant]
US 20120316324A1 · Adams et al. · 2012 [cited by applicant]
US 20130189262A1 · Wong et al. · 2013 [cited by applicant]
US 20140065142A1 · Roschke et al. · 2014 [cited by applicant]
US 20150079088A1 · Lowman et al. · 2015 [cited by applicant]
US 20160046730A1 · Ghayur et al. · 2016 [cited by applicant]
US 20160251440A1 · Roobrouck et al. · 2016 [cited by applicant]
US 20170106051A1 · Oh et al. · 2017 [cited by applicant]
US 20170298149A1 · Baeuerle et al. · 2017 [cited by applicant]
US 20180362655A1 · Wang et al. · 2018 [cited by applicant]
US 20190185562A1 · Regeneron · 2019 [cited by applicant]
US 20190330366A1 · Eckelman et al. · 2019 [cited by applicant]
US 20190352404A1 · Suzhou · 2019 [cited by applicant]
US 20190382500A1 · Abujoub et al. · 2019 [cited by applicant]
US 20200016202A1 · Kuchroo · 2020 [cited by applicant]
US 20200055946A1 · Timmer et al. · 2020 [cited by applicant]
US 20200157237A1 · Regev et al. · 2020 [cited by applicant]
US 20240026014A1 · Kastelein · 2024 [cited by examiner]
CN 111018985A · 2019 [cited by applicant]
WO 2008011081A2 · 2008 [cited by applicant]
WO 2009068631A1 · 2009 [cited by applicant]
WO 2013006544A1 · 2013 [cited by applicant]
WO 2013059299A1 · 2013 [cited by applicant]
WO 2015142675A2 · 2015 [cited by applicant]
WO 2016097313A1 · 2016 [cited by applicant]
WO 2017198212A1 · 2017 [cited by applicant]
WO 2019129221A1 · 2019 [cited by applicant]
WO 2019242632A1 · 2019 [cited by applicant]
WO 2020144164A1 · 2020 [cited by applicant]
WO 2020187711A1 · 2020 [cited by applicant]
WO 2022031871A1 · 2022 [cited by applicant]
WO 2022055641A1 · 2022 [cited by applicant]
Cairo, et al. “Control of multivalent interactions by binding epitope density.” Journal of the American Chemical Society 124, No. 8 (2002): 1615-1619. [cited by applicant]
De Weerd, et al. “The interferons and their receptors-distribution and regulation.” Immunology and cell biology 90, No. 5 (2012): 483-491. [cited by applicant]
Fan, et al. “Bispecific antibodies and their applications.” Journal of hematology & oncology 8 (2015): 1-14. [cited by applicant]
Goel, et al. “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response.” The Journal of Immunology 173, No. 12 (2004): 7358-7367. [cited by applicant]
Heldin, Carl-Henrik. “Dimerization of cell surface receptors in signal transduction.” Cell 80, No. 2 (1995): 213-223. [cited by applicant]
Holliger, et al. ““Diabodies”: small bivalent and bispecific antibody fragments.” Proceedings of the National Academy of Sciences 90, No. 14 (1993): 6444-6448. [cited by applicant]
Khan, et al. “Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies.” The Journal of Immunology 192, No. 11 (2014): 5398-5405. [cited by applicant]
Kontermann, Roland. “Dual targeting strategies with bispecific antibodies.” In MAbs, vol. 4, No. 2, pp. 182-197. Taylor & Francis, 2012. [cited by applicant]
Lo, et al. “Conformational epitope matching and prediction based on protein surface spiral features.” BMC genomics 22, No. 2 (2021): 1-16. [cited by applicant]
Lloyd, et al. “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens.” Protein Engineering, Design & Selection 22, No. 3 (2009): … [cited by applicant]
Marks, et al. “How repertoire data are changing antibody science.” Journal of Biological Chemistry 295, No. 29 (2020): 9823-9837. [cited by applicant]
Nie, et al. “Biology drives the discovery of bispecific antibodies as innovative therapeutics.” Antibody therapeutics 3, No. 1 (2020): 18-62. [cited by applicant]
Pingwara et al. IFN-λ Modulates the Migratory Capacity of Canine Mammary Tumor Cells via Regulation of the Expression of Matrix Metalloproteinases and Their Inhibitors. Cells. Apr. 23, 2021;10(5):999. [cited by applicant]
Saerens, et al. “Single-domain antibodies as building blocks for novel therapeutics.” Current opinion in pharmacology 8, No. 5 (2008): 600-608. [cited by applicant]
Shahangain et al., VVH Against VEGF-RBD, Genbank entry (online) National Center for Biotechnology Information, 12 May 215, retrieved from the internet www.ncbi.nlm.nih.gov/protein/BAR73350.1, 2 pages. [cited by applicant]
Shouval, et al. “Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans.” Advances in immunology 122 (2014): 177-210. [cited by applicant]
U.S. Appl. No. 18/006,370 , Advisory Action, Mailed On Jun. 4, 2024, 3 pages. [cited by applicant]
U.S. Appl. No. 18/006,370 , Final Office Action, Mailed On Mar. 15, 2024, 12 pages. [cited by applicant]
U.S. Appl. No. 18/006,370 , Non-Final Office Action, Mailed On Dec. 4, 2023, 36 pages. [cited by applicant]
Bhattacharya et al., “Impact of Genetic Variation on Three Dimensional Structure and Function of Proteins”, PLoS One, vol. 12, No. 3, Mar. 15, 2017, pp. 1-22. [cited by applicant]
Bork et al., “Go Hunting in Sequence Databases but Watch Out for the Traps”, Trends in Genetics, vol. 12, No. 10, Oct. 1996, pp. 425-427. [cited by applicant]
Bork , “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, Genome Research, vol. 10, No. 4, Apr. 2000, pp. 398-400. [cited by applicant]
Brenner , “Errors in Genome Annotation”, Trends in Genetics, vol. 15, No. 4, Apr. 1999, pp. 132-133. [cited by applicant]
Brorson et al., “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies”, The Journal of Immunology, vol. 163, No. 12, Dec. 15, 1999, pp. 6694-6701. [cited by applicant]
Brummell et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues”, Biochemistry, vol. 32, No. 4, Feb. 1993, pp. 1180-1187. [cited by applicant]
Burks et al., “In Vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket”, Proceedings of the National Academy of Sciences, vol. 94, No. 2, Jan. 21, 1997, pp. 412-417. [cited by applicant]
Colman , “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions”, Research in Immunology, vol. 145, No. 1, Jan. 1994, pp. 33-36. [cited by applicant]
Doerks et al., “Protein Annotation: Detective Work for Function Prediction”, Trends in Genetics, vol. 14, No. 6, Jun. 1998, pp. 248-250. [cited by applicant]
Fenton et al., “Rheostat Positions: A New Classification of Protein Positions Relevant to Pharmacogenomics”, Medicinal Chemistry Research, vol. 29, Jun. 7, 2020, pp. 1133-1146. [cited by applicant]
Guo et al., “Protein Tolerance to Random Amino Acid Change”, Proceedings of the National Academy of Sciences, vol. 101, No. 25, Jun. 14, 2004, pp. 9205-9210. [cited by applicant]
Ikeuchi et al., “Delicate Balance Among Thermal Stability, Binding Affinity, and Conformational Space Explored by Single-domain VHH Antibodies”, Scientific Reports, vol. 11, No. 1, Oct. 18, 2021, 9 pages. [cited by applicant]
Jang et al., “The Structural Basis for DNA Binding by an Anti-DNA Autoantibody”, Molecular Immunology, vol. 35, No. 18, Dec. 15, 1998, pp. 1207-1217. [cited by applicant]
Kobayashi et al., “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Binding by a High-Affinity Antibody”, Protein Engineering, vol. 12, No. 10, Oct. 1, 1999, pp. 879-884. [cited by applicant]
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Proceedings of the National Academy of Sciences, vol. 79, No. 6, Mar. 1, 1982, pp. 1979-1983. [cited by applicant]
Skolnick et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era”, Trends in Biotechnology, vol. 18, No. 1, Jan. 1, 2000, pp. 34-39. [cited by applicant]
Smith et al., “The Challenges of Genome Sequence Annotation or “The Devil is in the Details””, Nature Biotechnology, vol. 15, No. 12, Nov. 1997, pp. 1222-1223. [cited by applicant]
Tokuriki et al., “Stability Effects of Mutations and Protein Evolvability”, Current Opinion in Structural Biology, vol. 19, No. 5, Oct. 2009, pp. 596-604. [cited by applicant]
Vasudevan et al., “A Single Amino Acid Change in the Binding Pocket Alters Specificity of an Anti-Integrin Antibody AP7.4 as Revealed by Its Crystal Structure”, Blood Cells, Molecules, and Diseases, vol. 32, No. 1, Jan.… [cited by applicant]
Zhang et al., “Comprehensive Optimization of a Single-Chain Variable Domain Antibody Fragment as a Targeting Ligand for a Cytotoxic Nanoparticle”, mAbs, vol. 7, No. 1, Jan. 2015, pp. 42-52. [cited by applicant]
U.S. Appl. No. 18/006,370 , Notice of Allowance, Mailed On Jul. 26, 2024, 9 pages. [cited by applicant]
Akbar et al., “A Compact Vocabulary of Paratope-Epitope Interactions Enables Predictability of Antibodyantigen Binding”, Cell Reports, vol. 34, Mar. 16, 2021, 21 pages. [cited by applicant]
Cairo et al., “Control of Multivalent Interactions by Binding Epitope Density”, Journal of the American Chemical Society, vol. 124, No. 8, Feb. 2, 2002, pp. 1615-1619. [cited by applicant]
Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, Journal of Molecular Biology, vol. 334, No. 1, Nov. 14, 2003,… [cited by applicant]
Application No. PCT/US2021/044575 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 10 pages. [cited by applicant]
Application No. PCT/US2021/044575 , International Search Report and Written Opinion, Mailed On Feb. 2, 2022, 14 pages. [cited by applicant]
PCT/US2021/044575 “Invitation to Pay Additional Fees and, Where Applicable, Protest Fee”, Nov. 18, 2021, 2 pages. [cited by applicant]
Application No. PCT/US2021/044576 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 8 pages. [cited by applicant]
Application No. PCT/US2021/044576 , International Search Report and Written Opinion, Mailed On Jan. 12, 2022, 12 pages. [cited by applicant]
PCT/US2021/044576 , “Invitation to Pay Additional Fees and, Where Applicable, Protest Fee”, Nov. 12, 2021, 2 pages. [cited by applicant]
Application No. PCT/US2021/044577 , International Preliminary Report on Patentability, Mailed On Feb. 16, 2023, 7 pages. [cited by applicant]
Application No. PCT/US2021/044577 , International Search Report and Written Opinion, Mailed On Dec. 9, 2021, 10 pages. [cited by applicant]
Poosarla et al., “Computational de novo Design of Antibodies binding to a Peptide with High Affinity”, Biotechnology and Bioengineering, vol. 114, No. 6, Jan. 6, 2017, pp. 1331-1342. [cited by applicant]
Vajda et al., “Progress Toward Improved Understanding of Antibody Maturation”, Current Opinion in Structural Biology, vol. 67, Apr. 2021, pp. 226-231. [cited by applicant]